The efficacy of IFN-α in cutaneous T cell lymphoma (CTCL) was first reported in 1984 and also subsequently at the 1995 International Conference on CTCL to be the most effective single agent treatment. This evidence concerns the gene IFNA2 and primary cutaneous T-cell non-Hodgkin lymphoma.